LearnGlossaryMarketStocksSuperinvestorsSign in

IKT

Inhibikase Therapeutics, Inc.

Healthcare · $318M market cap

Verdict

We can't put a fair value on IKT right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-35.5% a year✗
Sales growth-28.5% a year✗
Free cash flow growth—?
Return on invested capital-48.3%✗

Follow IKT

Track it on your watchlist and see the full analysis. Free.

Create a free account

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works